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A 68 year old Caucasian male, with a past history of myasthenia gravis, peptic ulcer disease, vertebral com-
pression fractures and hypertension, presented to University Hospital with a two month history of anorexia 
and diarrhea.  The diarrhea was described as watery, greenish-brown stools occurring 4-5 times per day and 
during the night; no mucous or blood had been noted.  He reported a weight loss of 67 pounds over the past 
year and had been constantly fatigued.  He denied current fever, abdominal pain, nausea, vomiting, dys-
phagia or early satiety.  He had no recent travel or sick contacts and denied use of alcohol or illicit drugs.  The 
patient is a former smoker, with a 30 pack-year history of tobacco use. 
Of note, three weeks prior to this admission, he was admitted to the hospital for evaluation of nausea, vomit-
ing, diarrhea and melena.  During that hospitalization, an EGD revealed a large ulcer at the GE junction, mul-
tiple gastric ulcers and some duodenal ulcerations; biopsies were negative for H. pylori and a fasting gastric 
level was normal.  Clostridium difficile toxin and fecal leukocytes were positive and the patient was eventu-
ally discharged on a PPI and oral metronidazole.  His nausea and vomiting resolved but the diarrhea did not 
improve. 
Myasthenia gravis had been diagnosed one year prior to admission, when he presented with muscular weak-
ness and respiratory failure; he was discharged on prednisone 60 mg/day, pyridosigmine and monthly IVIG.  
The Neurology team added azathioprine seven months prior to the current admission and had been tapering 
his prednisone dose.  At the time of admission, he was on prednisone 10 mg/day, azathioprine 150 mg/day, 
pyridostigmine 60 mg 5x/day and the monthly IVIG. 
His physical exam on admission revealed normal vital signs; his oral mucosa was dry but he was in no acute 
distress.  HEENT was otherwise clear.  Neck was supple and nontender and there was no adenopathy or 
JVD.  Scant crackles were noted at the right lung base.  Cardiac exam was unremarkable, with no murmur, 
rub or gallop.  Abdomen was soft, nontender and not distended; bowel sounds were normal and there was 
no mass or organomegaly; there was some mild tenderness in the left hypochondrium.  Rectal exam was nor-
mal.  Neuromuscular exam was unremarkable with no focal deficits and with normal mentation; there was 
no peripheral edema, clubbing or cyanosis. 
Admission labs revealed WBC 3.6 (86G, 6L, 6M, 1.5E, .5B), Hgb 11.8, MCV 111, Platelets 158, Na 132, K 3.1, Cl 
91, HCO3 32, Gluc 98, BUN 19, Cr 0.8, TP 5.1, Alb 2.6, AP 48, AST 51, ALT 30, Amylase 136, Lipase 64.  His 
UA was normal.  HIV was negative.  Stools revealed the presence of leukocytes but were negative for Clos-
tridum difficile, giardia antigen, ova or parisites, AFB, routine culture, Microsporidia, Cryptosporidia, Cyc-
lospora and Isospora.  CMV IgG was positive but IgM was negative.  A CT Abd/Pelvis revealed mild thicken-
ing of the wall of the cecum and terminal ileum, an enhancing mass in the periphery of the right hepatic lobe, 
a cyst in the inferior right hepatic lobe, sigmoid diverticulosis and multiple old thoracolumbar vertebral com-
pression fractures. 
CMV DNA by PCR was ordered and GI was consulted for colonoscopy.  The latter showed ulceration around 
the ileo-cecal valve and scattered serpiginous ulcerations of the transverse and descending colon (as shown in 
figures 1 &2; next page).  Biopsies were taken and showed viral inclusions consistent with CMV (see figures 
3&4 on next page) and the CMV immune stain was positive.  The CMV DNA by PCR of the blood was also 
positive. 
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Figures 1 (right) and 2 (below) demon-
strate serpiginous ulcerations seen on 
colonoscopy (arrows) 
Figures 3 (above) and 4 (left) reveal the 
typical cytomegalic cells (arrows) indi-
cating infection with CMV.  The cells 
have a large, densely staining nucleus 
and abundant cytoplasm with intracyto-
plasmic inclusions. 
Rise  DISCUSSION:   
Cytomegalovirus (CMV) is a herpes virus that can cause a wide spectrum of disorders, ranging from subclinical 
infection to a disseminated disease in immunocompromised patients.  The primary infection can be obtained 
through sexual contact, blood or tissue exposure and is generally asymptomatic or may present as a mononucleo-
sis syndrome.  CMV can damage many organs, including lung, retina, liver and gastrointestinal tract.  Occasion-
ally, primary CMV infection can lead to severe, organ-specific complications.  Once the primary infection re-
solves, it enters a prolonged period of latency; latent infection is the presence of virus in tissue without secondary 
damage while CMV disease implies signs and symptoms of tissue injury.  In patients with latent CMV infection, 
disease may develop by reactivation of the virus or by infection with a novel exogenous strain; those who experi-
ence reactivation have adequate anti-CMV antibodies but have defective cell-mediated immunity due to condi-
tions such as AIDS, organ transplantation, chemotherapy or steroid therapy.  Gastrointestinal CMV disease is 
usually cause by reactivation of latent infection. 
A reasonable definition of gastrointestinal CMV disease is an erosive or ulcerative process in the wall of the GI 
tract in which the presence of CMV is demonstrated (by routine histologic examination, culture, antigen staining 
or DNA studies) and for which other causes have been excluded.  Histologic examination will reveal the presence 
of large cytomegalic cells, characterized by basophilic intranuclear inclusions, surrounded by a clear halo (owl’s 
eye), and clusters of intracytoplasmic inclusions. 
CMV can involve any part of the GI tract.  In the mouth, it may cause salivary gland infection or painful oral, 
pharyngeal or epiglottic ulcers.  In the esophagus, CMV infection may produce odynophagia and substernal pain 
due to solitary ulcers or strictures.  Gastric mucosal ulcerations may cause epigastric pain, nausea, vomiting or 
bleeding.  In the small intestine, CMV infection can cause terminal ileum disease and, rarely, obstruction.  The 
manifestations of colonic CMV disease are diarrhea, hematochezia, urgency, tenesmus, abdominal pain, fever, 
weight loss and, rarely, toxic megacolon (most often seen in AIDS patients). 
Diagnostic testing may be positive in latent infection and a positive result does not always indicate the presence 
of active disease; furthermore, testing may be negative in cases of active CMV.  Serologic testing includes the 
presence of IgM antibodies and/or a fourfold increase in IgG antiboidy titer  (at least 2-4 weeks apart); the benefit 
of serologic testing is limited by the fact that IgM antibody can persist for several months (or may be negative in 
active disease) and that IgG testing cannot provide a timely diagnosis.  Antigen detection includes early antigen 
in shell vial cultures and pp65 in peripheral blood leukocytes.  The former requires 2-3 days for detection, using 
monoclonal antibodies on biopsy specimens ( can be detected even before the cytopathic effects) while the latter 
requires 24 hours to yield results.  Diagnosis by culture (of blood, urine, CSF, bronchial washings, oropharyngeal 
secretions or biopsy tissue) will take weeks for cytopathic changes to occur.  The most sensitive way to detect 
CMV in blood or other fluids is by amplifying CMV DNA via the polymerase chain reaction (PCR) method.  The 
gold standard for diagnosis is a histopathologic examination of biopsy tissue, demonstrating cytomegalic cells 
by H&E stain and the presence of CMV antigen with immunoperoxidase staining. 
GI tract CMV infections are progressive and are associated with significant mortality if untreated.  The current 
treatment options are: Ganciclovir 5mg/kg IV, BID; Valganciclovir 900mg/day PO; Foscarnet 90mg/kg IV BID; 
Cidofovir 5 mg/kg IV weekly; all of these drugs inhibit DNA polymerase.  In addition, some reports have shown 
that octreotide may be effective for severe CMV colitis, although its mechanism of action remains unclear.  By 
expert consensus, the duration of treatment is 3-6 weeks and discontinuation of therapy should be based on reso-
lution of symptoms, disappearance of inclusion bodies and healing of ulcers (at 6 weeks).  If Ganciclovir is used, 
the CBC should be monitored twice weekly due to the potential side effects of neutropenia and thrombocyto-
penia; if severe thrombocytopenia is present, Foscarnet therapy should be considered.  However, Foscarnet can 
cause renal injury and hypocalcemia and labs should thus be monitored closely (twice weekly is recommended). 
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Rise  BACK TO OUR PATIENT: 
This 68 year old male was an immunosuppressed host due to his chronic therapy with prednisone and azathio-
prine for myasthenia gravis.  His positive IgG antibody for CMV indicates that he had a primary CMV infection 
in the past, which became latent.   Reactivation occurred due to the medication-induced immunosuppression and 
caused gastrointestinal CMV disease, specifically CMV colitis.  The patient was treated with Ganciclovir 5mg/kg 
IV BID and his azathioprine was held for the duration of his treatment in order to avoid additional bone marrow 
suppression.  He started to feel better, his diarrhea improved significantly and he was discharged on oral Valgan-
ciclovir 900 mg qd for 3 weeks; he will be followed in ID Clinic and the GI team will investigate the liver nodule 
(found incidentally on CT) in their clinic. 
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